NCT05375539View on ClinicalTrials.gov

AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

February 15, 2025

Study Completion Date

February 15, 2025

Conditions
Prostate Cancer
Interventions
DRUG

AGN-CognI.Q

Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.

Trial Locations (1)

17033

Penn State Cancer Institute, Hershey

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Milton S. Hershey Medical Center

OTHER

NCT05375539 - AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients | Biotech Hunter | Biotech Hunter